

press release

Novo Nordisk UK confirms no-deal Brexit plan

Gatwick, September 04 2018 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is committed to ensuring patients' insulin supply is unaffected in the event of a 'no-deal' Brexit.

Novo Nordisk is planning for future contingencies and its preparations include increasing stock of insulin products to approximately 16 weeks from Q4 2018. This significant increase builds on Novo Nordisk's robust plans for a 'no deal' scenario.

Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, "Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a 'no-deal' Brexit. We are working closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations.

Our decision to increase stock is in line with the technical notices and guidance published by the Government to industry. We are also working collaboratively with the Department of Health to ensure continuity of supply, irrespective of the outcome of Brexit negotiations."

-END-

About Novo Nordisk

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.co.uk

Further information

Juliet Scott +44 (0)7557490116
James Osborn +44 (0)1273 712000

zjls@novonordisk.com
james.osborn@thisispegasus.co.uk